# US 2010/0168219 A1 · Chronic inflammation and transplantation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168219 A1
- Document ID: US20100168219A1
- Status: Published application
- Kind: A1
- Application number: 12/319,004
- Filed: 2008-12-31
- Published: 2010-07-01
- Earliest claimed: 2008-12-31
- Inventors: Jonathan Steven Alexander
- Web page: https://patentgrep.com/patent/US20100168219A1

## CPC

- A61K 31/365: Lactones
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Neutrophils (PMN) can migrate along gradients of chemoattractants across endothelial monolayers to sites of inflammation and infection. This chemotaxis through endothelial cell borders is involved in several acute and chronic inflammatory diseases, however our understanding of the role of endothelial second messengers in the regulation of leukocyte emigration is still incomplete. We investigated this using an in vitro model of neutrophil migration across human umbilical vein endothelial cells (HUVECs) and human microvascular endothelial cells (HMECs) on cell culture inserts. We report that activation of endothelial protein kinase C (PKC) by both phorbol myristate acetate (PMA) and Bryostatin-1 (a potent PKCδ and c activator) can completely abolish neutrophil migration mediated by both endothelial TNF-α stimulation and a leukotriene B4 (LTB4) gradient. PMA protected against LTB4 induced PMN transmigration for at least 24 hours in HMECs and HUVECs. Bryostatin-1 protected PMN migration for at least 24 hours in HMECs and at least 48 hours in HUVECs. Pretreatment with Go-6983 (PKCα, β, and δ inhibitor) before the addition of Bryostatin-1 restored the loss of LTB4 induced neutrophil migration, while pretreatment with GO-6976 (PKCα and β inhibitor) did not. In addition using PKCδ and ε specific small interfering RNA, we were able to show that PKCδ, but not ε was at least mostly responsible for the loss of neutrophil migration in response to LTB4. Taken together, these observations suggest that activation of endothelial PKCδ could be therapeutic in the treatment of various inflammatory disorders characterized by enhanced neutrophil infiltration. This invention relates to pharmaceutical compositions, particularly pharmaceutical compositions comprising bryostatin-1 and substituted derivatives of bryostatin-1, thereof as pharmaceuticals for inhibition of inflammation, and for use in combating arteriosclerosis, diseases of the cardiovascular system, of the central nervous system and prior to/following organ transplantation, ischemia. The invention relates to methods for treating leukocyte dependent injury in chronic inflammatory diseases, and injury from transplantation mediated organ stress. The method involves injecting bryostatin-1 into patients with the inflammatory condition, treating the skin with bryostatin-1, or perfusing organs with bryostatin-1 prior to transplantation/cold storage. Activation of protein kinase Cd (PKCd) results in a near complete blockade of leukocyte infiltration which is the result of stabilization of the microvascular (endothelial) barrier.

## Claims

### Claim 1

A method of treating or preventing chronic inflammatory disease or transplantation injury, comprising the steps of administering an effective amount of bryostatin-1, bryostatin-1 analog or a pharmaceutically acceptable salt thereof to reduce or prevent induced neutrophil transendothelial migration.

### Claim 2 (depends on 1)

The method of claim 1 wherein said effective amount of bryostatin-1, bryostatin analog or pharmaceutically acceptable salt thereof is 10−7 M per 50 to 90 kg of individual being treated.

### Claim 3 (depends on 1)

The method of claim 1 wherein said effective amount of bryostatin-1, bryostatin analog or pharmaceutically acceptable salt thereof is 500 micrograms for 50 to 90 kg of individual being treated.

### Claim 4 (depends on 1)

The method of claim 1 wherein said effective amount bryostatin-1, bryostatin-1 analog or a pharmaceutically acceptable salt thereof is held in a dosage form.

### Claim 5 (depends on 4)

The method of claim 4 wherein said dosage form is an oral dosage form.

### Claim 6 (depends on 5)

The method of claim 5 wherein said oral dosage form is a solid oral dosage form.

### Claim 7 (depends on 4)

The method of claim 4 wherein said effective amount of bryostatin-1, bryostatin-1 analog or a pharmaceutically acceptable salt thereof is dispersed or dissolved in a saturated polyalkylene glycol glyceride.

### Claim 8 (depends on 7)

The method of claim 7 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbon to eighteen carbon saturated fatty acids with glycerol.

### Claim 9 (depends on 8)

The method of claim 8 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000.

### Claim 10 (depends on 9)

The method of claim 9 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1400 to 1600.

### Claim 11 (depends on 5)

The method of claim 5 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 1 to 30% by weight.

### Claim 12 (depends on 11)

The method of claim 11 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 10 to 20% by weight.

### Claim 13 (depends on 11)

The method of claim 11 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 2 to 25% by weight.

### Claim 14 (depends on 2)

The method of claim 2 wherein said dosage form is a pharmaceutical parenteral formulation.

### Claim 15 (depends on 14)

The method of claim 14 wherein said pharmaceutical formulation comprises polyalkylene glycol glyceride.

### Claim 16 (depends on 15)

The method of claim 15 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbon to eighteen carbon saturated fatty acids with glycerol.

### Claim 17 (depends on 15)

The method of claim 15 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000.

### Claim 18 (depends on 17)

The method of claim 17 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1400 to 1600.

### Claim 19 (depends on 14)

The method of claim 14 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 1 to 30% by weight.

### Claim 20 (depends on 19)

The method of claim 19 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 10 to 20% by weight.

### Claim 21 (depends on 19)

The method of claim 19 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation in an amount of 2 to 25% by weight.

### Claim 22 (depends on 14)

The method of claim 14 wherein said −1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation as a dispersion in water having a concentration of 0.5 to 70% by weight.

### Claim 23 (depends on 1)

The method of claim 1 wherein said chronic inflammatory disease or transplantation injury is in humans.

### Claim 24 (depends on 23)

The method of claim 23 wherein said chronic inflammatory disease or transplantation injury is leukocyte mediated tissue injury.

### Claim 25 (depends on 23)

The method of claim 23 wherein said chronic inflammatory disease or transplantation injury is mammalian ischemic, transplantation and leukocyte mediated injury and diseases.

### Claim 26

A dosage form for treating chronic inflammatory disease or transplantation injury comprising an effective amount of bryostatin-1, bryostatin-1 analog or a pharmaceutically acceptable salt thereof to reduce or prevent induced neutrophil transendothelial migration.

### Claim 27 (depends on 26)

The dosage form of claim 26 wherein said dosage form is a solid oral dosage form.

### Claim 28 (depends on 26)

The dosage form of claim 26 wherein said effective amount of bryostatin-1, bryostatin-1 analog or a pharmaceutically acceptable salt thereof is dispersed or dissolved in a saturated polyalkylene glycol glyceride.

### Claim 29 (depends on 28)

The dosage form of claim 28 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbon to eighteen carbon saturated fatty acids with glycerol.

### Claim 30 (depends on 29)

The dosage form of claim 29 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000.

### Claim 31 (depends on 30)

The dosage form of claim 30 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1400 to 1600.

### Claim 32 (depends on 31)

The dosage form of claim 31 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 1 to 30% by weight.

### Claim 33 (depends on 32)

The dosage form of claim 32 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 10 to 20% by weight.

### Claim 34 (depends on 27)

The dosage form of claim 27 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said oral dosage form in an amount of 2 to 25% by weight.

### Claim 35 (depends on 26)

The dosage form of claim 26 wherein said dosage form is a pharmaceutical parenteral formulation.

### Claim 36 (depends on 35)

The dosage form of claim 35 wherein said pharmaceutical parenteral formulation comprises polyalkylene glycol glyceride.

### Claim 37 (depends on 36)

The dosage form of claim 36 wherein said polyalkylene glycol glyceride is a mixture of polyalkylene esters of one or more eight carbon to eighteen carbon saturated fatty acids with glycerol.

### Claim 38 (depends on 37)

The dosage form of claim 37 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1000 to 2000.

### Claim 39 (depends on 38)

The dosage form of claim 38 wherein said polyalkylene glycol is a polyethylene glycol having a molecular weight of 1400 to 1600.

### Claim 40 (depends on 26)

The dosage form of claim 26 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 1 to 30% by weight.

### Claim 41 (depends on 40)

The dosage form of claim 40 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical formulation in an amount of 10 to 20% by weight.

### Claim 42 (depends on 26)

The dosage form of claim 26 wherein said bryostatin-1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation in an amount of 2 to 25% by weight.

### Claim 43 (depends on 26)

The dosage form of claim 26 wherein said −1, bryostatin-1 analog or pharmaceutically acceptable salt thereof is present in said pharmaceutical parenteral formulation as a dispersion in water having a concentration of 0.5 to 70% by weight.
